Furthermore, the different types of immunotherapies, particularly anti-PD1/anti-PD-L1 immune checkpoint inhibitors, have revolutionized the management of NSCLC, offering new effective therapeutic options for patients with previously limited treatment options. The gene discussed is CD274; the disease is non-small cell lung carcinoma.